JNJ · 10-Q · 2026Q2 · Full report

Neuroscience Demand Growth

JOHNSON & JOHNSON · 2026-07-23 · Importance 59 · Surprise 48 · No source text

Neuroscience sales increased 22.0% to $4.5 billion in fiscal six months 2026, with 20.5% operational growth. SPRAVATO sales grew 43.2%, driven by increased physician and patient demand. CAPLYTA benefited from continued momentum in its adjunctive treatment of Major Depressive Disorder launch. INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA grew 8.4%, primarily from favorable patient mix, partly offset by share loss and inventory dynamics.

Key facts

• CAPLYTA was acquired with Intra-Cellular Therapies on April 2, 2025 and contributed to neuroscience growth (CAPLYTA operational growth 70.9% in Q2). source
• SPRAVATO sales of $1,052 million for the fiscal six months ended June 28, 2026 increased 43.2% total, 42.0% operations and 1.2% currency versus prior year driven by continued increased physician and patient demand. source
• Neuroscience products achieved operational growth of 13.4% as compared to the same period a year ago for the fiscal second quarter. source

Impact estimates